Ozempic maker Novo Nordisk is to invest €432m in its Athlone facility to increase the manufacturing capacity for its Wegovy weight-loss product. Novo Nordisk has been a pioneer of the new wave of GLP-1 weight loss drugs, with Ozempic being in huge demand since it was launched. A new generation of weight loss drug,s which can be taken orally rather than as an injection are expected to grow sales further. Novo Nordisk currently employs 260 workers in Athlone. Dilek Dogan Gurluk, General Manager, Novo Nordisk Ireland said: "Ireland faces a significant public health challenge.

Source: Irish Examiner March 02, 2026 10:51 UTC